- Alphabet’s Google Cloud backlog is expected to drive significant revenue growth in 2026, with CFO Anat Ashkenazi mentioning a backlog of $240 billion. The company’s AI products and services are attracting more customers, leading to a backlog increase.
- BeOne Medicines, formerly BeiGene, could see approval for blood cancer therapy Brukinsa soon. The company is also awaiting results for sonrotoclax and plans to file for approval of BGB-16673 for chronic lymphocytic leukemia.
- Rhythm Pharmaceuticals is awaiting FDA approval for Imcivree in treating acquired hypothalamic obesity. The company expects to report data for other genetic diseases and Prader-Willi syndrome, potentially expanding its market reach.
Read more at Nasdaq: Prediction: These 3 Stocks Will Crush the Market in 2026